



HAL
open science

Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions

Etiena Basner-Tschakarjan, Federico Mingozzi

► **To cite this version:**

Etiena Basner-Tschakarjan, Federico Mingozzi. Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. *Frontiers in Immunology*, 2014, 5, pp.350. 10.3389/fimmu.2014.00350 . hal-01321133

HAL Id: hal-01321133

<https://hal.sorbonne-universite.fr/hal-01321133>

Submitted on 25 May 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions

Etiena Basner-Tschakarjan^{1*} and Federico Mingozi^{2,3*}

¹ Department of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

² University Pierre and Marie Curie, Paris, France

³ Genethon, Evry, France

Edited by:

Hildegard Büning, University of Cologne, Germany

Reviewed by:

Roland W. Herzog, University of Florida, USA

Hildegard Büning, University of Cologne, Germany

*Correspondence:

Etiena Basner-Tschakarjan, The Children's Hospital of Philadelphia, 3501 Civic Center Blvd Suite 5400, Philadelphia, PA 19104, USA
e-mail: basnertschakarjane@email.chop.edu;

Federico Mingozi, Genethon, 1 bis rue de l'Internationale, Evry 91000, France

e-mail: fmingozzi@genethon.fr

Adeno-associated virus (AAV) vectors are one of the most efficient *in vivo* gene delivery platforms. Over the past decade, clinical trials of AAV vector-mediated gene transfer led to some of the most exciting results in the field of gene therapy and, recently, to the market approval of an AAV-based drug in Europe. With clinical development, however, it became obvious that the host immune system represents an important obstacle to successful gene transfer with AAV vectors. In this review article, we will discuss the issue of cytotoxic T cell responses directed against the AAV capsid encountered on human studies. While over the past several years the field has acquired a tremendous amount of information on the interactions of AAV vectors with the immune system, a lot of questions are still unanswered. Novel concepts are emerging, such as the relationship between the total capsid dose and the T cell-mediated clearance of transduced cells, the potential role of innate immunity in vector immunogenicity highlighted in preclinical studies, and the cross talk between regulatory and effector T cells in the determination of the outcome of gene transfer. There is still a lot to learn about immune responses in AAV gene transfer, for example, it is not well understood what are the determinants of the kinetics of activation of T cells in response to vector administration, why not all subjects develop detrimental T cell responses following gene transfer, and whether the intervention strategies currently in use to block T cell-mediated clearance of transduced cells will be safe and effective for all gene therapy indications. Results from novel preclinical models and clinical studies will help to address these points and to reach the important goal of developing safe and effective gene therapy protocols to treat human diseases.

Keywords: AAV vectors, T cell responses, gene therapy, immunogenicity, immune modulation

INTRODUCTION

Several clinical studies have shown long-term correction of the disease phenotype following gene transfer (1–9). To attain this goal, two main approaches have been used, one using an integrating viral vector (typically retroviral or lentiviral) to introduce the therapeutic gene *ex vivo* into an autologous stem cell (10), the other transferring the gene into a post-mitotic cell *in vivo* (11).

Viral vectors derived from adeno-associated virus (AAV) have become the tool of choice for *in vivo* gene transfer, mainly because of their superior efficiency *in vivo* (11), their tropism for a broad variety of tissues, and their excellent safety profile. Therapeutic efficacy following AAV vector gene transfer was documented in several preclinical studies and, over the past decade, some of these results were successfully translated to the clinic, leading to some of the most exciting results in the field of gene therapy (11). The recent market approval of the first AAV-based gene therapy product in Europe (12, 13) constitutes additional evidence that the field is progressing from proof-of-concept studies toward clinical development.

However, human studies also highlighted some of the limitations of *in vivo* gene transfer with AAV vectors, which were not entirely identified in preclinical studies. In particular, it has been

shown that immune responses triggered by AAV vector-mediated gene transfer may constitute an important obstacle to long-term therapeutic efficacy and a safety concern.

Over the past 10 years, gene therapists have struggled with the issue of immunogenicity of AAV vectors. The initial lack of animal models recapitulating the findings in human trials (14–16) has made clinical observation crucial to understand the interactions between AAV vectors and the immune system. While recent work shows that it is possible to model human T cell responses to the AAV capsid in mice (17), it is likely that human studies will remain the main source of knowledge on immune responses in gene transfer. In this review article, we will summarize the progress that has been made in the understanding of T cell responses in AAV vector-mediated gene transfer focusing on human studies, we will discuss the current state of knowledge, and we will describe some of the proposed strategies to modulate AAV vector immunogenicity.

WILD-TYPE AAV AND RECOMBINANT AAV VECTORS

Adeno-associated virus are small non-enveloped viruses with a single-stranded DNA genome of ~4.7 kb composed by the *rep* and the *cap* genes, which encode for the proteins involved in the life cycle of the virus. The *rep* gene is involved in the virus replication,

while the *cap* gene encodes for the three structural proteins, VP1, VP2, and VP3, which form the viral capsid with a stoichiometry of 1:1:10, respectively (18), and for the assembly activating protein, which targets newly synthesized capsid proteins to the nucleolus and participates to their assembly into an icosahedral capsid (19). The *rep* and *cap* genes are flanked by two inverted terminal repeats (ITRs) that are needed as signals for packaging of the genome into the viral capsid (20). AAV is not autonomously replicating as its replication cycle depends on the coinfection with a helper virus such as adenovirus or herpes simplex; this explains why AAV was first isolated as a contaminant of an adenovirus preparation (21). The exposure to AAV and helper virus may account for the generation of both antibody and memory T cell response to AAV. AAV has never been associated with any known illnesses in humans with the exception of reports of association between spontaneous abortions and AAV infection (22). AAV vectors are derived from wild-type AAV by replacing all the viral coding sequences in the genome with an expression cassette for the transgene of interest. The ITRs are the only viral sequences retained in AAV vectors.

AAV VECTOR:HOST INTERACTIONS

Like other viral gene transfer vectors, AAV vectors are complex biological therapeutics, and the outcome of gene transfer is dependent on the interactions between vector- and host-related components (Figure 1). These interactions occur at multiple levels, starting from the innate recognition of the vector capsid and DNA genome (23), to the development of humoral (24) and cell-mediated adaptive responses to the capsid and/or the transgene product.

AAV VECTOR CAPSID

At the immunological levels, the AAV vector capsid is a replica of the wild-type virion, therefore, the vector capsid antigen is expected to be recognized by T cells like the wild-type AAV capsid antigen. Despite this important similarity, however, vector administration differs from natural infection as it involves the introduction of large numbers of viral particles into an organism, several logs more than in a natural infection (25), via routes substantially different from the natural route of exposure to AAV (i.e., mainly via the airways for wild-type AAV), and does not involve active replication of the virus or presence of a helper virus, as AAV vectors are delivered as preformed particles. These differences are also characteristic of other viral gene transfer platforms, however, unique features of AAV (e.g., their lower immunogenicity compared to adenovirus) may account for the outcome of AAV gene transfer in humans.

Because AAV vectors are non-replicating, it is generally assumed that the AAV capsid remains immunologically detectable within a transduced cell only for a defined period of time, which may vary from few weeks to several months, depending on the target tissue. Experiments in primates in the context of liver gene transfer suggest that the capsid is still detectable by the immune system several weeks following administration (26), indicated by the fact that interruption of immunosuppression (IS) 8 weeks after gene transfer results in a spike in anti-AAV antibodies. In dogs, intact capsid was detectable by electron microscopy in the retina up to 6 years following gene transfer (27), and a similar




FIGURE 1 | Adeno-associated virus vector: host interactions. The components of AAV vectors interact with the host in determining the outcome of gene transfer. For the AAV vector, the total capsid dose, the genome (single-stranded vs. self-complementary, CpG content, etc.), and the transgene product (to which the host may not be tolerant), represent some of the elements that could contribute to vector immunogenicity. On the host side, the characteristics of the target tissue (immunoprivilege, presence of inflammation, tolerogenic properties, etc.), the genetic background of the host (underlying disease-causing mutation, HLA haplotype, etc.), and the pre-exposure to the wild-type virus, can contribute to shape the overall response to vector delivery.

result was recently obtained in human muscle, in which immunostaining for capsid particles showed a positive signal 12 months following vector administration (28). Finally, results in humans undergoing AAV8 gene transfer for hemophilia B suggest that the capsid antigen in transduced hepatocytes is still recognizable by capsid-specific T cells 8–9 weeks following gene transfer (9).

Why the capsid persists for such a long period of time is not clear at this point. There are several factors that may influence the persistence of viral particles in a tissue, among them the vector serotype and dose administered, the degree of vascularization of the tissue target of transduction, the number of particles introduced in a single injection site, and the possible immune response to the vector itself, which may increase the rate of clearance of the antigen. *In vitro* studies attempting to determine the half-life of the capsid in transduced cells have been largely unsuccessful in predicting the fate of the capsid, mainly because of the poor infectivity of most serotypes in cell lines (29).

VECTOR DNA GENOME

Poorly defined until recently, the *in vitro* and *in vivo* interactions of both the DNA genome and the capsid of AAV vectors with the innate immune system were recently described by several groups (30–35). Additionally, recently published results indicate that the removal of CpG from the vector genome may contribute to reduce the potential immunogenicity of the transgene product (36). While these studies suggest that innate immunity to AAV vectors may trigger adaptive immune responses to the capsid or to the transgene product, there is no evidence that AAV vector administration in humans result in acute inflammatory reactions, although detailed studies in subjects undergoing AAV gene transfer remain to be performed.

TRANSGENE PRODUCT

Unlike the AAV vector capsid, which is not synthesized by infected cells, the transgene product is expressed for a long time after target tissue transduction (37–39). Vector-encoded transgene product may be recognized as a foreign antigen, especially if the recipient of gene transfer is not tolerant to the protein encoded by the vector, thus triggering immune responses that can result in production of transgene-specific neutralizing antibodies (40) or triggering of T cell responses directed against transgene-expressing transduced cells (41).

Preclinical studies suggest that the tissue target of transduction plays a fundamental role as determinant of transgene immune responses in gene transfer. For example, preclinical studies of intramuscular delivery of AAV vectors suggest that this approach carries a higher risk of triggering immune responses to the transgene (42) compared to other tissues such as the liver (43), and that the underlying disease-causing mutation is a major determinant of the risk of developing an immune response to the therapeutic transgene product following AAV-mediated gene transfer to the muscle (44). Conversely, delivery of AAV vectors to the muscle via the vasculature seem to reduce considerably the immunogenicity of the therapeutic transgene (45–47), suggesting that the more widespread and uniform transduction of muscle achieved with this route of vector delivery lowers transgene immunogenicity. Clinical results accumulated thus far on intramuscular delivery of AAV vectors seem to indicate that the approach is safe, as no subject enrolled in trials of intramuscular gene transfer developed anti-transgene immunity (13, 48, 49). Transgene-specific cell-mediated immunity was documented in only one study in which pre-existing immunity to dystrophin seemed to trigger the expansion of dystrophin-specific CD8⁺ T cell clones (41).

Differently from muscle, a number of studies showed that expression of a transgene in the liver is associated with induction of antigen-specific tolerance (43, 50–59). This was demonstrated for several antigens and in various animal models, including animals that were first immunized and then tolerized against the same antigen used for immunization using liver gene transfer (52, 55, 56).

Results from clinical gene transfer studies seem to support the hypothesis that AAV vector-mediated liver gene transfer is associated with tolerance, as no subject dosed with AAV vectors in the liver developed an immune response directed against the transgene product, including individuals carrying *null* mutations in the disease-causing gene (9, 60).

Lastly, one important point to keep in mind when discussing transgene immunity is that most of the clinical experience to date derives from studies in which cross-reactive immunologic material (CRIM) positive subjects and subjects with prior exposure to the therapeutic protein [e.g., recombinant or plasma-derived factor IX (FIX) for hemophilia B patients] were enrolled (9, 48, 60, 61). These categories of subjects are at lower risk of developing immune responses to the donated therapeutic gene, thus a careful assessment of the immunogenicity of the transgene in gene transfer will be necessary before enrolling previously untreated patients in gene transfer trials. Finally, also the disease state of the organ targeted with gene transfer can influence the magnitude of the immune responses observed following AAV vector-mediated gene transfer (62–64).

CAPSID ANTIGEN INTRACELLULAR PROCESSING AND MHC CLASS I PRESENTATION

Cell transduction with AAV vectors begins with binding of the virion to the cell surface proteins and carbohydrates, an event that is followed by endocytosis. The receptor and co-receptors used for cell entry vary among serotypes, although the receptors for all serotypes have not been identified yet. The steps of endosomal escape, nuclear transport, and vector uncoating are not completely understood in terms of timing or mechanism, this in part due to their complexity and the large number of pathways and compartments potentially involved in the process of cell transduction. The intracellular fate of AAV2 has been the most extensively investigated, because several cell lines are readily transduced by this serotype and because monoclonal antibodies recognizing AAV2 intact particles and capsid proteins were the first available. Of interest to this review article is the ability of the capsid antigen to be processed and cross-presented on MHC class I (MHC I) by transduced cells (e.g., hepatocytes). Since the initial findings on the immunogenicity of AAV2 vectors in human trials (60), the ability of replication-deficient AAV vectors to gain access to MHC I via cross-presentation has been object of debate, and several alternative hypothesis were formulated to explain why AAV2 vectors were immunogenic in humans but not in animal models. These included the possibility of preferential uptake of certain AAV serotypes by dendritic cells, the expression of *Cap* sequences packaged into AAV vectors, and the expression of alternative open reading frames within the transgene cDNA, which would generate aberrant proteins recognized as offending antigens by the host immune system [reviewed in Ref. (65)]. Several years of studies in preclinical models and, most importantly, in human trials (9) helped developing a better understanding of immune responses to AAV vectors, supporting the idea that capsid-specific T cell responses were responsible for clearance of transduced cells.

At the intracellular level, it has been shown that the capsid is substrate for ubiquitination (66, 67), and that proteasome inhibitors, or mutation of surface exposed tyrosine residues that normally undergo phosphorylation and ubiquitination, enhance transduction by enhancing nuclear uptake of virus (68, 69). Data supporting the hypothesis that the AAV capsid antigen is processed by the proteasome and presented on MHC I come from CTL assays performed using AAV-transduced human hepatocytes as targets, and HLA-matched capsid-specific CD8⁺ T cells as effectors (70). The fact that target cell lysis can be inhibited specifically using a capsid antigen-specific soluble T cell receptor (TCR) to block T cell access to the target cell (70) further confirms that the AAV capsid antigen is processed by transduced cells and presented on MHC I. Presentation of antigen in the context of MHC I was also demonstrated using a T cell line engineered to express luciferase when recognizing the capsid antigen (71). In this study, levels of antigen presentation were directly correlated with the multiplicity of infection used in the assay, and the proteasome inhibitor bortezomib blocked antigen presentation. These results are in agreement with results from clinical studies, which suggest the existence of a correlation between vector dose and magnitude of T cell responses to the capsid.

Recent work from Li et al. (72) indicates that the endosomal escape of vector is not only the pivotal step in cell transduction

but is also fundamental for capsid antigen presentation. While this is not completely surprising, the study also indicates that empty capsids, AAV particles that fail to encapsidate a DNA genome, are less likely to be presented onto MHC I. This result is somewhat in contrast with previous data showing that empty capsids do flag transduced cells for T cell recognition (70). One possible explanation for this difference is that the two studies used different strategies to detect antigen presentation: ovalbumin TCR transgenic T cells and a capsid carrying the ovalbumin SIINFEKL epitope in one study (72), or human peripheral blood mononuclear cells (PBMCs) expanded against a the native AAV epitope VPQYGYLTL to track presentation of native AAV2 capsid antigen (70). Immunogenicity of empty vs. full AAV capsids is an important pending question for the field, particularly given the fact that empty capsids may play an important beneficial role in allowing for vector transduction in the presence of neutralizing antibodies (73).

Although there is no direct evidence that intracellular processing and presentation of AAV onto MHC I differ among serotypes, anecdotal evidence supporting this hypothesis comes, for example, from the observation that the administration of AAV2 and AAV8 vectors to the liver of humans at similar doses results in different kinetics of activation cytotoxic T cell immunity against the transduced hepatocytes (9, 60, 74). Whether these differences can be ascribed to the vector serotype only is unknown, as *in vitro* studies comparing AAV serotypes have been challenging due to differences in efficiency of AAV transduction among serotypes. Conversely, *in vivo* preclinical studies show somewhat contrasting results, some suggesting for example that AAV2 and AAV8 have identical kinetics of T cell induction (75), and others showing that AAV2 and AAV8 do differ in their ability of triggering T cell proliferation (76). Serotype-specific differences are also supported by data generated with an adoptive T cell transfer model in mice, indicating that AAV8 remains immunologically detectable longer than AAV2 following systemic gene transfer to target the liver (17, 76).

In conclusion, several studies identified the key intracellular AAV trafficking steps that are involved in cell transduction and capsid antigen presentation. Whether there is one leading pathway for antigen cross-presentation or rather multiple alternative pathways concur to MHC I presentation (77) of capsid remains to be defined. Most importantly, the significance of *in vitro* findings has to be proven *in vivo*, as kinetics and pathways might differ substantially in living organisms compared to cell lines.

T CELL RESPONSES TO AAV IN HUMAN STUDIES

Several studies on the seroprevalence of AAV in humans suggest that exposure to the wild-type virus mostly occurs early in life (78–80). Similarly, monitoring of T cell reactivity to the AAV2 capsid conducted in humans undergoing splenectomy for non-malignant indications shows that about two-thirds of adults >25 year-old carry a pool of T cells that can produce IFN- γ in response to AAV2 capsid peptides, while only a small proportion of subjects <5 years old present T cell reactivity to the capsid (81). Veron et al. (82) conducted a similar survey for AAV1 in PBMCs from healthy donors. In this study, an overall frequency of respondents of about 30% was documented. The difference in frequency of subjects carrying capsid-specific T cells in the two studies may be due to the

fact that reactive T cells fail to circulate in peripheral blood at high frequency [as previously suggested in Ref. (74)], or to the different restimulation protocols used (a peptide library was used in the AAV2 study vs. lentiviral vectors expressing capsid were used in the AAV1 study), or else it may reflect inherent differences in the frequency of subjects exposed to AAV2 vs. AAV1.

Two aspects of capsid T cell reactivity are worth noting, the first is that the high degree of conservation of the AAV capsid amino acid sequence (83) results in a high degree of cross-reactivity of T cell responses across serotypes (74). The second aspect is that B and T cell responses to AAV seem to be uncoupled, as subjects positive for anti-AAV antibodies may not present detectable T cell reactivity to the capsid and, vice versa, subjects with detectable T cell reactivity to AAV in PBMC have lower anti-capsid antibody titers (82). This suggests that, following exposure to AAV, certain individuals may develop a Th1 response to the antigen, while others develop a predominantly Th2 response. Future studies will be required to clarify the relationship between B and T cell responses to AAV in the context of the natural infection with the virus.

LIVER-DIRECTED GENE TRANSFER

The importance of T cell immunity to the AAV capsid in terms of both safety and efficacy of AAV gene transfer in humans was initially evidenced in the first clinical trial in which an AAV2 vector was introduced into the liver of severe hemophilia B subjects (60). In this study, upon AAV gene transfer to liver, two subjects developed transient elevation of liver enzymes and loss of FIX transgene expression around week 4 post vector delivery due to the immune rejection of transduced hepatocytes mediated by capsid-specific CD8⁺ T cells (74).

While conceptually these findings are not surprising, as antiviral immunity is expected to recognize virus infected cells and clear them, this was the first instance in which a cytotoxic immune response directed against the AAV capsid was observed in the context of gene transfer. Preclinical animal studies failed to predict or to recapitulate the findings in humans, and initial attempts to model the induction of destructive T cell responses in mice have been mostly unsuccessful until recently (17).

The recent findings in a clinical trial of AAV8 gene transfer of FIX to the liver of subjects affected by severe hemophilia B (9) confirmed results in the previous AAV2 trial and supported the hypothesis that AAV capsid antigen is processed and presented onto MHC I by vector-transduced hepatocytes where it is recognized by capsid-specific CD8⁺ T cells, leading to clearance of vector-transduced hepatocytes, transaminase elevation, and loss of FIX transgene expression.

In particular, in the AAV8-FIX study vector administration resulted in the activation of capsid-specific CD8⁺ T cells, with an increase in liver enzymes that required intervention with corticosteroids detected in four out of six subjects (9, 84) from the high-dose cohort, who received 2×10^{12} vg/kg of vector, ~8–9 weeks after vector delivery. Results from this clinical study suggest that a short course of steroids, administered at the time of liver enzymes elevation and loss of transgene expression, can at least partially rescue transgene expression. This study also highlights differences in kinetics of T cell responses between the AAV2 and the AAV8 liver trials, as liver enzyme elevation in the AAV2 trial was observed

around week 4 following vector delivery (60), as opposed to the 8- to 9-weeks in the AAV8 trial (9). It is not clear at this point what is the likely explanation for this difference.

One important emerging aspect of AAV capsid-driven capsid T cell reactivity in humans is that capsid-specific T cell responses seem to be detected in a dose-dependent fashion, a result consistent with published *in vitro* antigen presentation data (70). Above a certain threshold of capsid antigen dose, the activation of capsid-specific T cells results in loss of transduced hepatocytes. Whether at vector doses higher than those tested thus far all subjects will mount a T cell response that will result in loss of transgene expression, and whether steroids will effectively control capsid T cells at all vector doses, is not clear at this point. Several factors are likely to influence the outcome of vector administration in humans in terms of T cell reactivity, thus complicating the interpretation of results, among them the HLA type of the subjects infused, the concomitant presence of inflammation in the target tissue, and other vector-specific features that may enhance immune responses to the vector, the transgene, or both.

GENE TRANSFER TO THE MUSCLE

Adeno-associated virus vector-induced T cell immunity is not unique to liver-directed gene transfer. Monitoring of capsid T cell responses has been performed in the context of several muscle-directed gene transfer clinical studies (41, 85–92) as well. In agreement with the findings in AAV liver gene transfer studies, results accumulated for muscle gene transfer suggest that the magnitude of T cell responses directed against the AAV capsid correlates with the dose of vector administered (65, 92). Following intramuscular AAV vector delivery, an increase in frequency of circulating reactive T cells in PBMC is observed at higher vector doses (91). In some cases, detection of capsid T cell activation in PBMC correlated with lack of transgene expression in vector injected muscle (89, 91); while in other studies the detection of capsid T cells in PBMC seemed to have no effect on transgene persistence (28).

Immunosuppression has been used in some of the muscle gene transfer studies conducted thus far to modulate capsid immunogenicity (13). Whether this helped the persistence of transgene expression is not completely clear due to the lack of readily detectable efficacy endpoints and the fact that IS itself complicates immunomonitoring as it is likely to modify capsid-directed T cell responses.

In a recent study of intramuscular gene transfer for α_1 -antitrypsin deficiency (92), vector administration was associated with detection of capsid-specific T cell reactivity and increase in serum creatine kinase in some subjects around day 30 post vector administration. Furthermore, activation of both CD4⁺ and CD8⁺ T cells in peripheral blood and T cell infiltrates in muscle biopsies were detected. T cell reactivity against the AAV capsid antigen did not seem to result in clearance of transduced muscle fibers or loss of transgene expression, a finding that may be explained by the fact that significant amounts of CD4⁺CD25⁺FoxP3⁺ regulatory T cells (Tregs) were found in muscle biopsies (28). Whether the local induction of Tregs is a phenomenon unique to muscle or to the α_1 -antitrypsin transgene (93) remains to be established. However, these findings indicate that proinflammatory and tolerogenic signals may be concomitantly elicited by vector administration and

may concur in determining the outcome of gene transfer. Similarly, apoptosis of transgene reactive T cells in muscle has been documented in mice (94) and in humans (90), indicating that additional factors are involved in the modulation immunogenicity of vector and transgene other than the target organ alone.

The inability of collecting tissue biopsies in the AAV trials for hemophilia conducted thus far prevented investigators from comparing results between liver and muscle gene transfer, thus leaving open important questions on the relevance of tissue-specific features that may influence vector immunogenicity.

GENE TRANSFER TO IMMUNOPRIVILEGED BODY SITES

Adeno-associated virus vectors have been administered to humans in several eye- (95) and brain- (96–102) targeted gene transfer trials. So far, doses tested in these immunoprivileged body compartments were lower compared to the doses tested in the liver or muscle trials, and they fail to elicit significant antibody or cell-mediated immune responses to capsid or transgene product. While these results strongly support the safety of gene transfer to eye and brain, future studies will help to understand whether the immune privilege is maintained at all vector doses, especially given the fact that some AAV vector serotypes can escape the blood–brain barrier (103), thus resulting in systemic exposure to the vector.

OVERCOMING T CELL IMMUNITY TO AAV

More than 10 years have passed since the initial AAV2 FIX trial. The field of *in vivo* gene transfer with AAV vectors has progressed enormously thanks to a multitude of preclinical and clinical studies that clarified the nature of anti-capsid immune responses and tested the efficacy of strategies aimed at preventing or modulating these responses. In this section of our review article, we will discuss some of these strategies, with particular emphasis on those already tested in the clinic.

REDUCE THE TOTAL CAPSID ANTIGEN DOSE

Results from the AAV8 hemophilia trial (9, 84) suggest that lower vector doses may not trigger destructive T cell responses to the capsid. In this study, subjects who received vectors doses up to 6×10^{11} vg/kg did not experience increase in liver enzymes or loss of transgene expression, at the same time levels of FIX transgene were just above the threshold for therapeutic efficacy. Different strategies are being tested to maintain the total capsid dose low while increasing therapeutic efficacy. One is to use hyperactive variants of the therapeutic protein (104–106), or stronger promoter elements (107), or else codon-optimized transgenes (108, 109). All these maneuvers are either being tested in the clinic or about to enter clinical trials and results will be available soon.

Engineering the AAV capsid to prevent its presentation onto MHC I (17, 69) or administration of proteasome inhibitors (71) to block processing of capsid antigen are also strategies that have been proposed to reduce capsid antigen load following vector administration. These strategies are also associated with higher transduction efficiency in animal models (71, 110), thus they could potentially allow to decrease the therapeutic dose; however, the role of alternative antigen presentation pathways should be taken into account when evaluating this strategy. Furthermore, the use of proteasome inhibitors like bortezomib is not devoid of potentially serious side effects (111).

The use of AAV vector preparations devoid of empty capsids is also being tested as a strategy to reduce the overall antigen load associated with gene transfer. While clearly this results in lower total amounts of capsid being administered, in the negative side it may render vectors more susceptible for antibody-mediated neutralization (73). The jury is still out on the role of empty capsids in gene transfer, with some reports suggesting that these particles are not immunogenic (72), others arguing that they are detrimental for transduction efficiency (112), and recent reports showing that they are beneficial in the presence of anti-AAV neutralizing antibodies (73).

USE TRANSIENT IMMUNOSUPPRESSION

One potential advantage of the use of IS in the context of AAV gene transfer is that, differently from organ transplant or autoimmune disease, the duration of the intervention is expected to be relatively short (9). Initial studies of gene transfer with IS favored the idea of treating subjects upfront, starting just before or at the time of vector administration (26, 58, 113–116). The advantage of this approach is that any immune response occurring after vector delivery would be prevented, the main disadvantage consists in the fact that IS would prevent efficient immunomonitoring, thus would not allow to study the nature and kinetics of immunity to AAV. Additionally, treating all subjects with IS may not be necessary, as some may not develop immunity to the vector (9, 84).

Aside from the obvious higher risk of infection, IS may also influence induction of Tregs (58), which are fundamental for the maintenance of transgene tolerance in liver (43) gene transfer and seem to play an important role in muscle gene transfer (28). Recent reports show impaired transduction levels under IS with mycophenolate mofetil (113), others report a longer plasma half-life of vector in non-human primates receiving IS (114). These are all evidences that interactions of IS with viral gene transfer are quite complex and may result in unexpected findings.

The use of transient IS with steroids at the time of liver enzyme elevation is a relatively novel concept in the field of gene transfer that has been successfully adopted in the AAV8 hemophilia trial. In this study, a mild elevation of liver enzymes has been immediately treated with high-dose prednisolone, resulting in the prevention of what appeared to be an immune-mediated clearance of AAV8 transduced hepatocytes. The main advantage of the approach is that not all subjects were exposed to IS, in fact only those who had increased liver enzymes received prednisolone. The challenge of the approach is that endpoints of liver (or other organ) immunotoxicity may not be always obvious, making a targeted intervention hard. In these latter cases, upfront IS may be necessary; however, the key question revolves around the timing and the duration of this approach. Additionally, steroids may not work in some subjects or at high vector doses. These concerns will be addressed in future studies.

In conclusion, one important consideration about IS regimens and timing of intervention is about the immune state of infused subjects. Some individuals may in fact be recently primed by natural infections with wild-type AAV, or else could have been previously enrolled in gene therapy protocols (in case of vector readministration). Immune responses to the vector capsid in these

subjects may be expected to be faster and stronger, thus warranting particular attention.

CAN WE TOLERIZE SUBJECTS AGAINST THE AAV CAPSID?

As an alternative to IS, the induction of Tregs specific to the AAV capsid can result in sustained expression of the transgene with no induction of destructive T cells.

MHC class II epitopes found in human IgG (117) have been described to induce proliferation of Tregs and suppress Th1 and Th2 immune responses (117–120). These peptides, named Tregitopes, have been used to modulate CD8⁺ T cell responses to AAV, resulting in suppression of cytotoxic responses against AAV-transduced cells and expansion of Tregs *in vitro*. Additional studies *in vivo* (118), in which Tregitopes were co-expressed with the capsid antigen, resulted in modulation of CD8⁺ T cell responses to the capsid antigen itself following adenoviral vector-mediated vaccination. While results *in vitro* suggest that the approach leads to antigen-specific tolerance (118), additional studies are needed to test if antigen-specificity is conserved *in vivo*, whether the approach is safe, and ultimately, how to translate this strategy to the clinic.

CONCLUSION

Since the initial proof-of-concept studies, the field of *in vivo* gene transfer has progressed enormously. Experience from the clinical translation of AAV vector-based gene transfer strategies has highlighted the challenges and helped optimize the choice of the AAV vector serotype, the delivery methods, and has highlighted some of the limitations of the approaches tested. In particular, the interactions between the human immune system and all the components of gene therapy vectors seem to represent one of the major limitations to long-lasting therapeutic efficacy.

The small scale of gene transfer trials for rare diseases, the heterogeneity of vector serotypes, transgenes, and doses tested, and the ability of measuring the endpoints of therapeutic efficacy have been an obstacle to the advancement of knowledge. Furthermore, individual variability associated with HLA haplotype and with the underlying disease state also represents an added layer of complexity to data interpretation.

Gene therapists should not forget that immune responses triggered by gene transfer must be understood and studied as a complex network of interactions; as such, the outcome of gene transfer in immunological terms is influenced by both innate and adaptive immunity, which are influenced by the nature of the vector, transgene, route, etc. Future immunosurveillance studies conducted in clinical gene transfer studies will provide the basis for a better understanding of the determinants of T cell responses in AAV-mediated gene transfer, for example, the role of target tissue inflammation due to the underlying disease. Standardization of technologies used for monitoring of T cell responses (121, 122) will help to correlate them with clinical outcomes and, eventually, devise novel strategies around the issue.

Despite these challenges, the field has acquired critical information from the studies conducted thus far, which allowed to address the issue of vector immunogenicity. The results of these efforts are evident, long-term follow up data from AAV gene transfer

trials show many examples of long-lasting therapeutic efficacy. And results accumulating suggest that once transgene expression is established, and immune responses avoided, multi-year therapeutic efficacy is a goal attainable in humans.

ACKNOWLEDGMENTS

This work was supported by Genethon (Federico Mingozzi), by the European Union FP7-PEOPLE-2012-CIG grant 333628 and ERC-2013-CoG grant 617432 (Federico Mingozzi), by the Bayer grant ECIA (Federico Mingozzi), by a grant from the National Institutes of Health (P01HL78810, Etiena Basner-Tschakarjan), and The Children's Hospital of Philadelphia.

REFERENCES

- Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metaphromatic leukodystrophy. *Science* (2013) **341**:1233158. doi:10.1126/science.1233158
- Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. *Science* (2013) **341**:1233151. doi:10.1126/science.1233151
- Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. *Proc Natl Acad Sci U S A* (2008) **105**:15112–7. doi:10.1073/pnas.0807027105
- Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. *N Engl J Med* (2009) **360**:447–58. doi:10.1056/NEJMoa0805817
- Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. *N Engl J Med* (2008) **358**:2231–9. doi:10.1056/NEJMoa0802268
- Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. *Science* (2009) **326**:818–23. doi:10.1126/science.1171242
- Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. *Nature* (2010) **467**:318–22. doi:10.1038/nature09328
- Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. *N Engl J Med* (2008) **358**:2240–8. doi:10.1056/NEJMoa0802315
- Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. *N Engl J Med* (2011) **365**:2357–65. doi:10.1056/NEJMoa1108046
- Naldini L. Ex vivo gene transfer and correction for cell-based therapies. *Nat Rev Genet* (2011) **12**:301–15. doi:10.1038/nrg2985
- Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. *Nat Rev Genet* (2011) **12**:341–55. doi:10.1038/nrg2988
- Buning H. Gene therapy enters the pharma market: the short story of a long journey. *EMBO Mol Med* (2013) **5**:1–3. doi:10.1002/emmm.201202291
- Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. *Gene Ther* (2013) **20**:361–9. doi:10.1038/gt.2012.43
- Li C, Hirsch M, Asokan A, Zeithaml B, Ma H, Kafri T, et al. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. *J Virol* (2007) **81**:7540–7. doi:10.1128/JVI.00529-07
- Li H, Murphy SL, Giles-Davis W, Edmonson S, Xiang Z, Li Y, et al. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. *Mol Ther* (2007) **15**:792–800. doi:10.1038/mt.sj.6300090
- Wang L, Figueredo J, Calcedo R, Lin J, Wilson JM. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. *Hum Gene Ther* (2007) **18**:185–94. doi:10.1089/hum.2007.001
- Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. *Blood* (2013) **121**:2224–33. doi:10.1182/blood-2012-10-460733
- Muzyczka N, Berns KI. *Parvoviridae: The Viruses and Their Replication*. Philadelphia, PA: Lippincott, Williams and Wilkins (2001).
- Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. *Proc Natl Acad Sci U S A* (2010) **107**:10220–5. doi:10.1073/pnas.1001673107
- Zhou X, Muzyczka N. In vitro packaging of adeno-associated virus DNA. *J Virol* (1998) **72**:3241–7.
- Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. *Science* (1965) **149**:754–6. doi:10.1126/science.149.3685.754
- Arechavala-Velasco F, Gomez L, Ma Y, Zhao J, McGrath CM, Sammel MD, et al. Adverse reproductive outcomes in urban women with adeno-associated virus-2 infections in early pregnancy. *Hum Reprod* (2008) **23**:29–36. doi:10.1093/humrep/dem360
- Rogers GL, Martino AT, Aslanidi GV, Jayandharan GR, Srivastava A, Herzog RW. Innate immune responses to AAV Vectors. *Front Microbiol* (2011) **2**:194. doi:10.3389/fmicb.2011.00194
- Calcedo R, Wilson JM. Humoral immune response to AAV. *Front Immunol* (2013) **4**:341. doi:10.3389/fimmu.2013.00341
- Zwart MP, Hemerik L, Cory JS, de Visser JA, Bianchi FJ, Van Oers MM, et al. An experimental test of the independent action hypothesis in virus-insect pathosystems. *Proc Biol Sci* (2009) **276**:2233–42. doi:10.1098/rspb.2009.0064
- Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA, et al. Effects of transient immunosuppression on adeno-associated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. *Blood* (2006) **108**:3321–8. doi:10.1182/blood-2006-04-017913
- Stieger K, Le Meur G, Lasne F, Weber M, Deschamps JY, Nivard D, et al. Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. *Mol Ther* (2006) **13**:967–75. doi:10.1016/j.yjmt.2006.08.510
- Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. *J Clin Invest* (2013) **123**:5310–8. doi:10.1172/JCI70314
- Ellis BL, Hirsch ML, Barker JC, Connelly JP, Steininger RJ III, Porteus MH. A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with nine natural adeno-associated virus (AAV1–9) and one engineered adeno-associated virus serotype. *Virol J* (2013) **10**:74. doi:10.1186/1743-422X-10-74
- Hosel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P, et al. Toll-like receptor 2-mediated innate immune response in human non-parenchymal liver cells toward adeno-associated viral vectors. *Hepatology* (2012) **55**:287–97. doi:10.1002/hep.24625
- Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, et al. The genome of self-complementary adeno-associated viral vectors increases toll-like receptor 9-dependent innate immune responses in the liver. *Blood* (2011) **117**:6459–68. doi:10.1182/blood-2010-10-314518
- Zaiss AK, Cotter MJ, White LR, Clark SA, Wong NC, Holers VM, et al. Complement is an essential component of the immune response to adeno-associated virus vectors. *J Virol* (2008) **82**:2727–40. doi:10.1128/JVI.01990-07
- Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. *J Virol* (2002) **76**:4580–90. doi:10.1128/JVI.76.9.4580-4590.2002
- Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. *J Clin Invest* (2009) **119**:2388–98. doi:10.1172/JCI37607
- Sudres M, Cire S, Vasseur V, Brault L, Da Rocha S, Boisgerault F, et al. MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV. *Mol Ther* (2012) **20**:1571–81. doi:10.1038/mt.2012.101
- Faust SM, Bell P, Cutler BJ, Ashley SN, Zhu Y, Rabinowitz JE, et al. CpG-depleted adeno-associated virus vectors evade immune detection. *J Clin Invest* (2013) **123**:2994–3001. doi:10.1172/JCI68205
- Nathwani AC, Rosales C, McIntosh J, Rastegarlarlari G, Nathwani D, Raj D, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. *Mol Ther* (2011) **19**:876–85. doi:10.1038/mt.2010.274

38. Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. *Blood* (2012) **119**:3038–41. doi:10.1182/blood-2011-09-382317
39. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. *Blood* (2009) **113**:797–806. doi:10.1182/blood-2008-10-181479
40. Fields PA, Arruda VR, Armstrong E, Chu K, Mingozzi F, Hagstrom JN, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. *Mol Ther* (2001) **4**:201–10. doi:10.1006/mthe.2001.0441
41. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et al. Dystrophin immunity in Duchenne's muscular dystrophy. *N Engl J Med* (2010) **363**:1429–37. doi:10.1056/NEJMoa1000228
42. Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. *Gene Ther* (2005) **12**:1453–64. doi:10.1038/sj.gt.3302539
43. Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. *J Clin Invest* (2003) **111**:1347–56. doi:10.1172/JCI16887
44. Rogers GL, Martino AT, Zolotukhin I, Ertl HC, Herzog RW. Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. *J Transl Med* (2014) **12**:25. doi:10.1186/1479-5876-12-25
45. Arruda VR, Stedman HH, Haurigot V, Buchlis G, Baila S, Favaro P, et al. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. *Blood* (2010) **115**:4678–88. doi:10.1182/blood-2009-12-261156
46. Haurigot V, Mingozzi F, Buchlis G, Hui D, Chen Y, Basner-Tschakarjan E, et al. Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. *Mol Ther* (2010) **18**:1318–29. doi:10.1038/mt.2010.73
47. Toromanoff A, Adjali O, Larcher T, Hill M, Guigand L, Chenuaud P, et al. Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. *Mol Ther* (2010) **18**:151–60. doi:10.1038/mt.2009.251
48. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. *Blood* (2003) **101**:2963–72. doi:10.1182/blood-2002-10-3296
49. Strokes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. *Arterioscler Thromb Vasc Biol* (2008) **28**:2303–4. doi:10.1161/ATVBAHA.108.175620
50. Sun B, Bird A, Young SP, Kishnani PS, Chen YT, Koeberl DD. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. *Am J Hum Genet* (2007) **81**:1042–9. doi:10.1086/522236
51. Zhang P, Sun B, Osada T, Rodriguez R, Yang XY, Luo X, et al. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. *Hum Gene Ther* (2012) **23**:460–72. doi:10.1089/hum.2011.063
52. Annoni A, Cantore A, Della Valle P, Goudy K, Akbarpour M, Russo F, et al. Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. *EMBO Mol Med* (2013) **5**:1684–97. doi:10.1002/emmm.201302857
53. Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, et al. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. *Blood* (2007) **110**:1132–40. doi:10.1182/blood-2007-02-073304
54. Dobrzynski E, Mingozzi F, Liu YL, Bendo E, Cao O, Wang L, et al. Induction of antigen-specific CD4+ T-cell anergy and deletion in vivo viral gene transfer. *Blood* (2004) **104**:969–77. doi:10.1182/blood-2004-03-0847
55. Finn JD, Ozelo MC, Sabatino DE, Franck HW, Merricks EP, Crudele JM, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. *Blood* (2010) **116**:5842–8. doi:10.1182/blood-2010-06-288001
56. Markusic DM, Hoffman BE, Perrin GQ, Nayak S, Wang X, LoDuca PA, et al. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. *EMBO Mol Med* (2013) **5**:1698–709. doi:10.1002/emmm.201302859
57. Martino AT, Nayak S, Hoffman BE, Cooper M, Liao G, Markusic DM, et al. Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity. *PLoS One* (2009) **4**:e6376. doi:10.1371/journal.pone.0006376
58. Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, Sabatino DE, et al. Modulation of tolerance to the transgene product in a non-human primate model of AAV-mediated gene transfer to liver. *Blood* (2007) **110**:2334–41. doi:10.1182/blood-2007-03-080093
59. Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. *Blood* (2004) **103**:3700–9. doi:10.1182/blood-2003-09-3217
60. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. *Nat Med* (2006) **12**:342–7. doi:10.1038/nm1358
61. Ferreira V, Petry H, Salmon F. Immune responses to AAV-vectors, the Glybera example from bench to bedside. *Front Immunol* (2014) **5**:82. doi:10.3389/fimmu.2014.00082
62. Boisgerault F, Gross DA, Ferrand M, Poupiot J, Darocha S, Richard I, et al. Prolonged gene expression in muscle is achieved without active immune tolerance using microRNA 142.3p-regulated rAAV gene transfer. *Hum Gene Ther* (2013) **24**:393–405. doi:10.1089/hum.2012.208
63. Breous E, Somanathan S, Bell P, Wilson JM. Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver. *Gastroenterology* (2011) **141**(1): 348–57, 357.e1–3. doi:10.1053/j.gastro.2011.04.002
64. Matzinger P. The danger model: a renewed sense of self. *Science* (2002) **296**:301–5. doi:10.1126/science.1071059
65. Mingozzi F, High KA. Immune responses to AAV in clinical trials. *Curr Gene Ther* (2011) **11**:321–30. doi:10.2174/156652311796150354
66. Ding W, Zhang L, Yan Z, Engelhardt JF. Intracellular trafficking of adeno-associated viral vectors. *Gene Ther* (2005) **12**:873–80. doi:10.1038/sj.gt.3302527
67. Yan Z, Zak R, Luxton GW, Ritchie TC, Bantel-Schaal U, Engelhardt JF. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. *J Virol* (2002) **76**:2043–53. doi:10.1128/jvi.76.5.2043-2053.2002
68. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. *J Clin Invest* (2000) **105**:1573–87. doi:10.1172/JCI8317
69. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. *Proc Natl Acad Sci U S A* (2008) **105**:7827–32. doi:10.1073/pnas.0802866105
70. Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD, Hasbrouck NC, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. *J Clin Invest* (2009) **119**:1688–95. doi:10.1172/JCI36891
71. Finn JD, Hui D, Downey HD, Dunn D, Pien GC, Mingozzi F, et al. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. *Mol Ther* (2010) **18**:135–42. doi:10.1038/mt.2009.257
72. Li C, He Y, Nicolson S, Hirsch M, Weinberg MS, Zhang P, et al. Adeno-associated virus capsid antigen presentation is dependent on endosomal escape. *J Clin Invest* (2013) **123**:1390–401. doi:10.1172/JCI66611
73. Mingozzi F, Anguela XM, Pavani G, Chen Y, Davidson RJ, Hui DJ, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. *Sci Transl Med* (2013) **5**:194ra192. doi:10.1126/scitranslmed.3005795
74. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. *Nat Med* (2007) **13**:419–22. doi:10.1038/nm1549
75. He Y, Weinberg MS, Hirsch M, Johnson MC, Tisch R, Samulski RJ, et al. Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical. *Hum Gene Ther* (2013) **24**:545–53. doi:10.1089/hum.2013.065

76. Wu TL, Li H, Faust SM, Chi E, Zhou S, Wright F, et al. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome. *Mol Ther* (2014) **22**:42–51. doi:10.1038/mt.2013.218
77. Oliveira CC, van Hall T. Importance of TAP-independent processing pathways. *Mol Immunol* (2013) **55**:113–6. doi:10.1016/j.molimm.2012.10.005
78. Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. *Gene Ther* (2012) **19**:288–94. doi:10.1038/gt.2011.90
79. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). *J Med Virol* (1999) **59**:406–11. doi:10.1002/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N
80. Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. *Clin Vaccine Immunol* (2011) **18**:1586–8. doi:10.1128/CVI.05107-11
81. Hui DJ, Basner-Tschakarjan E, Chen Y, Edmonson SC, Maus MV, Podsakoff GM, et al. Characterization of AAV T cell epitopes presented by splenocytes from normal human donors. *Mol Ther ASGCT Annu Meet Abstr* (2012) **20**(Suppl 1):S557.
82. Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, Moullier P, et al. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. *J Immunol* (2012) **188**:6418–24. doi:10.4049/jimmunol.1200620
83. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. *Proc Natl Acad Sci U S A* (2002) **99**:11854–9. doi:10.1073/pnas.182412299
84. Basner-Tschakarjan E, Mingozzi F, Chen Y, Nathwani A, Tuddenham E, Riddell A, et al. Cellular immune responses to vector in a gene therapy trial for hemophilia b using an AAV8 self-complementary factor IX vector. *Blood Am Soc Hematol Annu Meet* (2013) **122**:21.
85. Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. *Proc Natl Acad Sci U S A* (2009) **106**:16363–8. doi:10.1073/pnas.0904514106
86. Flotte TR, Schwiebert EM, Zeitlin PL, Carter BJ, Guggino WB. Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. *Hum Gene Ther* (2005) **16**:921–8. doi:10.1089/hum.2005.16.921
87. Herson S, Hentati F, Rigolet A, Behin A, Romero NB, Leturcq F, et al. A phase I trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. *Brain* (2012) **135**:483–92. doi:10.1093/brain/awr342
88. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial. *J Card Fail* (2009) **15**:171–81. doi:10.1016/j.cardfail.2009.01.013
89. Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. *Ann Neurol* (2010) **68**:629–38. doi:10.1002/ana.22251
90. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, Kota J, Coley BD, Galloway G, et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. *Ann Neurol* (2009) **66**:290–7. doi:10.1002/ana.21732
91. Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. *Blood* (2009) **114**:2077–86. doi:10.1182/blood-2008-07-167510
92. Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, Rouhani F, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha-1-antitrypsin: interim results. *Hum Gene Ther* (2011) **22**:1239–47. doi:10.1089/hum.2011.053
93. Ozeri E, Mizrahi M, Shahaf G, Lewis EC. Alpha-1 antitrypsin promotes semi-mature, IL-10-producing and readily migrating tolerogenic dendritic cells. *J Immunol* (2012) **189**:146–53. doi:10.4049/jimmunol.1101340
94. Velazquez VM, Bowen DG, Walker CM. Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy. *Blood* (2009) **113**:538–45. doi:10.1182/blood-2008-01-131375
95. Willett K, Bennett J. Immunology of AAV-mediated gene transfer in the eye. *Front Immunol* (2013) **4**:261. doi:10.3389/fimmu.2013.00261
96. Leone P, Shera D, McPhee SW, Francis JS, Kolodny EH, Bilaniuk LT, et al. Long-term follow-up after gene therapy for Canavan disease. *Sci Transl Med* (2012) **4**:165ra163. doi:10.1126/scitranslmed.3003454
97. McPhee SW, Janson CG, Li C, Samulski RJ, Camp AS, Francis J, et al. Immune responses to AAV in a phase I study for Canavan disease. *J Gene Med* (2006) **8**:577–88. doi:10.1002/jgm.885
98. Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, Neyzi N, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. *Hum Gene Ther* (2008) **19**:463–74. doi:10.1089/hum.2008.022
99. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. *Neurology* (2009) **73**:1662–9. doi:10.1212/WNL.0b013e3181c29356
100. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. *Lancet* (2007) **369**:2097–105. doi:10.1016/S0140-6736(07)60982-9
101. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. *Lancet Neurol* (2010) **9**:1164–72. doi:10.1016/S1474-4422(10)70254-4
102. Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, et al. Safety and tolerability of intraputamenal delivery of CER-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. *Lancet Neurol* (2008) **7**:400–8. doi:10.1016/S1474-4422(08)70065-6
103. Haurigot V, Marco S, Ribera A, Garcia M, Ruza A, Villacampa P, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. *J Clin Invest* (2013) **123**(8):3254–71. doi:10.1172/JCI66778
104. Finn JD, Nichols TC, Svoronos N, Merricks EP, Bellenger DA, Zhou S, et al. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. *Blood* (2012) **120**:4521–3. doi:10.1182/blood-2012-06-440123
105. Siner JI, Iacobelli NP, Sabatino DE, Ivanciu L, Zhou S, Poncz M, et al. Minimal modification in the factor VIII B domain sequence ameliorates the murine hemophilia A phenotype. *Blood* (2013) **121**:4396–403. doi:10.1182/blood-2012-10-464164
106. Cantore A, Nair N, Della Valle P, Di Matteo M, Matrai J, Sanvito F, et al. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. *Blood* (2012) **120**:4517–20. doi:10.1182/blood-2012-05-432591
107. Nair N, Rincon MY, Evens H, Sarcar S, Dastidar S, Samara-Kuko E, et al. Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy. *Blood* (2014) **123**:3195–9. doi:10.1182/blood-2013-10-534032
108. Ward NJ, Buckley SM, Waddington SN, Vandendriessche T, Chuah MK, Nathwani AC, et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. *Blood* (2011) **117**:798–807. doi:10.1182/blood-2010-05-282707
109. McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. *Blood* (2013) **121**:3335–44. doi:10.1182/blood-2012-10-462200
110. Nathwani AC, Cochrane M, McIntosh J, Ng CY, Zhou J, Gray JT, et al. Enhancing transduction of the liver by adeno-associated viral vectors. *Gene Ther* (2009) **16**:60–9. doi:10.1038/gt.2008.137
111. Alé A, Bruna J, Navarro X, Udina E. Neurotoxicity induced by antineoplastic proteasome inhibitors. *Neurotoxicology* (2014). doi:10.1016/j.neuro.2014.02.001
112. Gao K, Li M, Zhong L, Su Q, Li J, Li S, et al. Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effects. *Mol Ther Methods Clin Dev* (2014) **1**:9. doi:10.1038/mtm.2013.9

113. Montenegro-Miranda PS, ten Bloemendaal L, Kunne C, de Waart DR, Bosma PJ. Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors. *Hum Gene Ther* (2011) **22**:605–12. doi:10.1089/hum.2010.222
114. Unzu C, Hervas-Stubbs S, Sampedro A, Mauleon I, Mancheno U, Alfaro C, et al. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. *J Transl Med* (2012) **10**:122. doi:10.1186/1479-5876-10-122
115. Wang Z, Storb R, Halbert CL, Banks GB, Butts TM, Finn EE, et al. Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. *Mol Ther* (2012) **20**:1501–7. doi:10.1038/mt.2012.111
116. Finn JD, Favaro P, Wright JF, Mingozi F, High KA, Arruda VR. Rabbit antithymocyte globulin (rATG) administered concomitantly with liver delivery of AAV2-hFIX can promote inhibitor formation in rhesus macaques. *Blood* (2010) **116**:3765.
117. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. *Blood* (2008) **112**:3303–11. doi:10.1182/blood-2008-02-138073
118. Hui DJ, Basner-Tschakarjan E, Chen Y, Davidson RJ, Buchlis G, Yazicioglu M, et al. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. *Mol Ther* (2013) **21**:1727–37. doi:10.1038/mt.2013.166
119. Cousens LP, Su Y, McClaine E, Li X, Terry F, Smith R, et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. *J Diabetes Res* (2013) **2013**:621693. doi:10.1155/2013/621693
120. van der Marel S, Majowicz A, Kwikkers K, van Logtenstein R, te Velde AA, De Groot AS, et al. Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. *World J Gastroenterol* (2012) **18**:4288–99. doi:10.3748/wjg.v18.i32.4288
121. Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, et al. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. *Cancer Immunol Immunother* (2011) **60**:15–22. doi:10.1007/s00262-010-0940-z
122. Britten CM, Walter S, Janetzki S. Immunological monitoring to rationally guide AAV gene therapy. *Front Immunol* (2013) **4**:273. doi:10.3389/fimmu.2013.00273

Conflict of Interest Statement: Federico Mingozi is inventor in patents describing the AAV vector technology and technologies to modulate immunity to AAV. Etiena Basner-Tschakarjan reports no conflicts of interest.

Received: 08 April 2014; accepted: 08 July 2014; published online: 23 July 2014.

Citation: Basner-Tschakarjan E and Mingozi F (2014) Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. *Front. Immunol.* **5**:350. doi: 10.3389/fimmu.2014.00350

This article was submitted to *Microbial Immunology*, a section of the journal *Frontiers in Immunology*.

Copyright © 2014 Basner-Tschakarjan and Mingozi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.